Trevi Therapeutics, Inc.
TRVI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001563880
In the last 90 days, Trevi Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 218 institutions reported holding it in 13F filings for Q2 2026, worth $2.76B in total; Viking Global Investors is the only superinvestor holding it.
Q2 2021 vs. Q1 2021
How the institutions holding Trevi Therapeutics, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 19 | 17 | −2 |
| Shares | 13.1M | 12.5M | −650.2K (−5.0%) |
| Value | $35.6M | $28.1M | −$7.51M (−21.1%) |
New holders (2)
Institutions that held Trevi Therapeutics, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Alberta Investment Management Corp | 25,000 | $56.0K | 0.00% |
| Barclays PLC | 100 | $0 | 0.00% |
Sold out (4)
Institutions that held Trevi Therapeutics, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| FMR LLC | 576,500 | $1.57M |
| Citadel Advisors LLC | 10,617 | $29.0K |
| Morgan Stanley | 1,000 | $3.00K |
| Bank of America Corp | 16 | $0 |